Arformoterol Tartrate and Hepatic impairment

• Generic Name: arformoterol
• Dosage Forms: n.a.
• Other Brand Names: Brovana

Long-term treatment of bronchoconstriction associated with COPD, including chronic bronchitis and emphysema.

Long-acting β2-adrenergic agonists recommended as maintenance therapy in patients with moderate (e.g., forced expiratory volume in 1 second [FEV1] ≥50 but <80% of predicted) to very severe COPD (e.g., FEV1 <30% of predicted or <50% of predicted plus chronic respiratory failure) who have persistent symptoms not relieved by as-needed therapy with short-acting bronchodilators (e.g., ipratropium, β2-adrenergic agonist).

Regular treatment with long-acting bronchodilators more effective and convenient than treatment with short-acting bronchodilators. Superiority of one long-acting bronchodilator over another currently not established. If inadequate response, may use a combination of long-acting bronchodilators, such as a long-acting inhaled anticholinergic agent (tiotropium) and a long-acting β2-adrenergic agonist.

In patients with severe (e.g., FEV1 <50% of predicted, history of repeated exacerbations) to very severe COPD, add regular treatment with an inhaled corticosteroid to long-acting bronchodilator therapy. If inadequate response or limiting adverse effects occur, add or substitute extended-release oral theophylline.

Not to be used for immediate relief of acute exacerbations of COPD. Use short-acting inhaled β2-agonist intermittently (as needed) for acute symptoms of COPD. (See Acute Exacerbations of COPD under Cautions.) Efficacy and safety of long-acting bronchodilators, with or without inhaled corticosteroids, during acute exacerbations of COPD not established.